Wednesday, October 14, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 17, 2026

Stellantis, Wayve, and Uber Partner to Scale Robotaxis Globally

View original at globenewswire.com
Stellantis, Wayve, and Uber Partner to Scale Robotaxis Globally Stellantis, Wayve, and Uber Partner to Scale Robotaxis Globally Stellantis, Wayve, and Uber are collaborating to develop and deploy L4 driverless mobility services By combining Stellantis’ world-class vehicle L4-Ready Platforms™, Wayve’s advanced AI Driver…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Uber has completed more than 75 billion trips since its founding in 2010.

    60% confidence

  • Successfully scaling autonomous mobility requires seamlessly combining the right vehicles, technology, and platform.

    60% confidence

  • The three-way partnership signals industry convergence around Wayve's technology as the leading approach to scale autonomous vehicles globally.

    60% confidence

  • The collaboration will deliver smarter, safer, and more efficient mobility by combining Stellantis' L4-Ready Platforms with Wayve's adaptive AI and Uber's global network to accelerate AV deployment that meets real customer needs at scale.

    60% confidence

  • Wayve's AI driving technology is designed to adapt across different regions and driving conditions without relying on city-by-city mapping or re-engineering, enabling faster and more cost-effective expansion.

    60% confidence

Data points we hold from this source

Uber Technologies · trips completed75 billion_trips
Uber Technologies · founding year2010 year
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Stellantis, Wayve, and Uber Partner to Scale Robotaxis Globally — Source | Via News | Via News